The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.
 
Allison Betof Warner
Consulting or Advisory Role - BluePath Solutions; Bristol-Myers Squibb/Medarex; immatics; Instil Bio; Iovance Biotherapeutics; Lyell Immunopharma; Novartis; Pfizer
Research Funding - Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
James William Smithy
Research Funding - IO Biotech
 
Michael A. Postow
Consulting or Advisory Role - Bristol-Myers Squibb; Cancer Expert Now; Chugai Pharma; Eisai; Erasca, Inc; Intellisphere; Merck; MJH Associates; Nektar; Novartis; Pfizer; WebMD
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
 
Katherine Panageas
Stock and Other Ownership Interests - 23andMe; Adicet Bio; Chinook Therapeutics; Codexis; T2 Biosystems; Vincerx Pharma
Research Funding - AACR (Inst)
Travel, Accommodations, Expenses - The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Awards) in collaboration with the American Association for Cancer Research (AACR), Bristol Myers Squibb Foundation
 
Adam Jacob Schoenfeld
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Enara Bio; Heat Biologics; Immunocore; Iovance Biotherapeutics; Johnson & Johnson/Janssen; KSQ Therapeutics; Legend Biotech; Lyell Immunopharma; Merck; Oppenheimer; Perceptive Advisors; Prelude Therapeutics; Umoja Biopharma
Research Funding - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
Travel, Accommodations, Expenses - Instil Bio; Iovance Biotherapeutics
Other Relationship - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
 
Jedd D. Wolchok
Leadership - Ludwig Institute for Cancer Research
Stock and Other Ownership Interests - Apricity Therapeutics; Arsenal IO; Ascentage Pharma; CellCarta; Georgiamune; Imvaq Therapeutics; Larkspur; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; XenImmune Therapeutics
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; BeiGene; Bicara Therapeutics; Bristol-Myers Squibb; CellCarta; Chugai Pharma; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Surface Oncology; Takeda; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Sephora (Inst)
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); ANTIGEN-RECOGNIZING RECEPTORS TARGETING B7-H3 AND USES THEREOF (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); CD40 binding Molecules and uses thereof (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy (Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy (Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Erasca, Inc; Novartis
Research Funding - Alkermes (Inst); Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Targovax (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate